Cerulean Newswire

Comprehensive Real-Time News Feed for Cerulean.

Results 1 - 20 of 24 in Cerulean

  1. Cerulean Pharma Inc. Establishes Clinical Collaboration With To Study ...Read the original story

    19 hrs ago | BioSpace

    Cerulean Pharma Inc. , a leader in Dynamic Tumor Targetinga , today announced it has signed a clinical research agreement with the GOG Foundation Inc. to conduct an open-label Phase 1b clinical trial of its lead product candidate, CRLX101, in combination with weekly paclitaxel in patients with relapsed ovarian cancer. Cerulean and the GOG Foundation have commenced start-up procedures and expect to enroll the first patient in the second quarter of 2015.

    Comment?

  2. Cerulean to Present at Two Upcoming ConferencesRead the original story

    Yesterday | Business Wire

    )-- Cerulean Pharma Inc. (Nasdaq: CERU), a leader in Dynamic Tumor Targetinga , today announced that Christopher D. T. Guiffre, JD, MBA, Chief Operating Officer, will present at the following conferences: 27th Annual ROTH Conference in Laguna Nigel, ...

    Comment?

  3. Cerulean to Present at Two Upcoming ConferencesRead the original story

    Tuesday Feb 3 | Freshnews

    Cerulean Pharma Inc. , a leader in Dynamic Tumor Targeting, today announced that Christopher D. T. Guiffre, JD, MBA, Chief Operating Officer, will present at the 7th Annual BIO CEO & Investor Conference in New York on Tuesday, February 10, 2015, at 9:30 a.m. ET. Mr. Guiffre also will participate in an analyst-led fireside chat at the Leerink Partners 2015 Global Healthcare Conference in New York on Thursday, February 12, 2015, at 1:00 p.m. ET.

    Comment?

  4. Cerulean to Present at Two Upcoming ConferencesRead the original story

    Tuesday Feb 3 | Business Wire

    )-- Cerulean Pharma Inc. (Nasdaq:CERU), a leader in Dynamic Tumor Targetinga , today announced that Christopher D. T. Guiffre, JD, MBA, Chief Operating Officer, will present at the 7th Annual BIO CEO & Investor Conference in New York on Tuesday, ...

    Comment?

  5. Cerulean Appoints Vice President, Clinical OperationsRead the original story

    Jan 29, 2015 | Freshnews

    Cerulean Pharma Inc. , a leader in Dynamic Tumor Targeting, today announced the appointment of Tiffany Crowell as Vice President, Clinical Operations. "Tiffany comes to Cerulean with deep experience and demonstrated leadership in clinical development and operations that will be crucial in supporting our clinical development of CRLX101 and CRLX301," said Paul Friedman, MD, Executive Chairman of Cerulean.

    Comment?

  6. CRLX101 Rectal Cancer Data Presented at ASCO 2015 Gastrointestinal Cancers SymposiumRead the original story

    Jan 19, 2015 | Freshnews

    Cerulean Pharma Inc. , a leader in Dynamic Tumor Targeting, today announced that preclinical data and initial clinical data from a Phase 1b/2 investigator-sponsored trial of CRLX101 in combination with chemoradiotherapy in non-metastatic rectal cancer was presented at the ASCO 2015 Gastrointestinal Cancers Symposium held January 15-17, 2015. Andrew Wang, MD, Department of Radiation Oncology, UNC Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, the Principle Investigator on the trial, presented a poster entitled Improving neoadjuvant chemoradiotherapy for rectal cancer with CRLX101, a nanoparticle-drug conjugate, with a camptothecin payload.

    Comment?

  7. CRLX101 Rectal Cancer Data Presented at ASCO 2015 Gastrointestinal Cancers SymposiumRead the original story

    Jan 19, 2015 | Business Wire

    Preclinical data support adding CRLX101 to chemoradiotherapy and Phase 1b/2 trial of CRLX101 plus chemoradiotherapy trial further reveals no dose limiting toxicities to date )-- Cerulean Pharma Inc. , a leader in Dynamic Tumor Targetinga , today announced that preclinical data and initial clinical data from a Phase 1b/2 investigator-sponsored trial of CRLX101 in combination with chemoradiotherapy in non-metastatic rectal cancer was presented at the ASCO 2015 Gastrointestinal Cancers Symposium held January 15-17, 2015.

    Comment?

  8. Cerulean gets up to $27M in new funding from HerculesRead the original story

    Jan 8, 2015 | Business Journal

    In advance of some key trial data on its cancer drugs to be announced in the next couple months, Cerulean Pharma says it has gained access to as much as $27 million in new funding from Hercules Technology Growth Capital.

    Comment?

  9. Cerulean Announces Publication Describing Synergistic Anti-Tumor...Read the original story

    Jan 6, 2015 | Freshnews

    Cerulean Pharma Inc. , a leader in Dynamic Tumor Targeting, today announced that Clinical Cancer Research published a manuscript describing preclinical data demonstrating that CRLX101, Cerulean's proprietary investigational drug, has potent anti-tumor activity alone and in combination with AvastinA in advanced metastatic ovarian cancer. These preclinical data also demonstrate that CRLX101 reduced the up-regulation of HIF-1I by Avastin, which is believed to be a mechanism of resistance to anti-angiogenic therapy.

    Comment?

  10. Cerulean Announces First Patient Dosed with CRLX301 in Phase 1/2a Trial in Advanced Solid TumorsRead the original story

    Dec 17, 2014 | Freshnews

    Cerulean Pharma Inc. , a leader in Dynamic Tumor Targeting, today announced that the first patient has been dosed with CRLX301 in Cerulean's Phase 1/2a trial in patients with advanced solid tumor malignancies. CRLX301 is a nanoparticle-drug conjugate, or NDC, with a docetaxel payload, and it is the second clinical candidate from Cerulean's Dynamic Tumor Targeting Platform.

    Comment?

  11. Cerulean Pharma Inc. Announces First Patient Dosed With CRLX301 In...Read the original story

    Dec 16, 2014 | BioSpace

    Cerulean Pharma Inc. , a leader in Dynamic Tumor Targetinga , today announced that the first patient has been dosed with CRLX301 in Cerulean's Phase 1/2a trial in patients with advanced solid tumor malignancies. CRLX301 is a nanoparticle-drug conjugate, or NDC, with a docetaxel payload, and it is the second clinical candidate from Cerulean's Dynamic Tumor Targeting Platform.

    Comment?

  12. Cerulean Announces Completion of Enrollment of a Phase 1b/2 Study of...Read the original story

    Dec 15, 2014 | Freshnews

    Cerulean Pharma Inc. , a leader in Dynamic Tumor Targeting, today announced completion of enrollment of 22 patients in a Phase 1b/2 clinical proof of principle trial of its lead nanoparticle-drug conjugate, CRLX101, in combination with AvastinA in relapsed renal cell carcinoma . This study is an investigator-sponsored trial being conducted by the University of Pennsylvania and Thomas Jefferson University Hospital with support from Cerulean.

    Comment?

  13. Cerulean Pharma Inc. Reports Third-Quarter 2014 Corporate Highlights And Financial ResultsRead the original story

    Nov 14, 2014 | BioSpace

    Cerulean Pharma Inc. , a leader in Dynamic Tumor Targetinga , today provided an update on corporate activities during the quarter ended September 30, 2014. "Cerulean launched an important randomized Phase 2 trial in the third quarter," said Paul A. Friedman, M.D., Executive Chairman of Cerulean.

    Comment?

  14. Cerulean Pharma Inc. To Host Third-Quarter 2014 Conference Call On November 13Read the original story

    Oct 30, 2014 | BioSpace

    Cerulean Pharma Inc. , a leader in Dynamic Tumor Targetinga , today announced it will provide an update on corporate activities for the third quarter of 2014 on November 13. Paul Friedman, M.D., Executive Chairman and Chris Guiffre, Chief Operating Officer will conduct a conference call at 4:30 p.m. that day to provide a business update and review the Company's third-quarter financial results. The call can be accessed by dialing 831-3031 or 637-1284 prior to the start of the call and referencing conference ID: 25500996.

    Comment?

  15. Cerulean to Host Third-Quarter 2014 Conference Call on November 13Read the original story w/Photo

    Oct 30, 2014 | GlobeNewswire

    Cerulean Pharma Inc. , a leader in Dynamic Tumor Targeting, today announced it will provide an update on corporate activities for the third quarter of 2014 on November 13. Paul Friedman, M.D., Executive Chairman and Chris Guiffre, Chief Operating Officer will conduct a conference call at 4:30 p.m. that day to provide a business update and review the Company's third-quarter financial results. The call can be accessed by dialing 831-3031 or 637-1284 prior to the start of the call and referencing conference ID: 25500996.

    Comment?

  16. Cerulean CEO resigns to head up San Diego biotechRead the original story w/Photo

    Oct 28, 2014 | Business Journal

    The CEO of one of the many newly public Cambridge-based biotech firms, Cerulean Pharma, has resigned as of Wednesday this week to become head of San Diego-based Synthetic Genomics.

    Comment?

  17. Cerulean Pharma Inc. Appoints To Board Of DirectorsRead the original story

    Oct 28, 2014 | BioSpace

    Cerulean Pharma Inc. , a leader in Dynamic Tumor Targetinga , today announced the appointment of clinical oncology expert, David Parkinson, M.D., to its Board of Directors, effective as of October 29, 2014. With Dr. Parkinson's appointment, Cerulean has formed a Clinical Advisory Committee of the Board, which will consist of Dr. Parkinson, Dr. Susan Kelley and Dr. Paul Friedman.

    Comment?

  18. Cerulean Pharma Inc. CEO Steps DownRead the original story

    Oct 28, 2014 | BioSpace

    Cerulean Pharma Inc. , a leader in Dynamic Tumor Targetinga , today announced that Oliver Fetzer, Ph.D., has resigned as President and Chief Executive Officer, effective as of October 29, 2014, to pursue other professional opportunities. Paul Friedman, M.D., who currently serves on Cerulean's Board of Directors, will assume the position of Executive Chairman of the Board.

    Comment?

  19. Cerulean Pharma Inc. Appoints Vice President, Regulatory AffairsRead the original story

    Oct 6, 2014 | BioSpace

    Cerulean Pharma Inc. , a leader in Dynamic Tumor Targetinga , today announced the appointment of Pamela Strode as Vice President, Regulatory Affairs. "Pam has extensive regulatory and oncology experience across all phases of product development, from pre-clinical through the post marketing life-cycle, as well as strategic expertise that will help Cerulean advance its nanoparticle-drug conjugates, or NDCs, through the clinic to commercialization," said Oliver Fetzer, Ph.D., President and Chief Executive Officer of Cerulean.

    Comment?

  20. Cerulean Appoints General CounselRead the original story

    Sep 29, 2014 | Hispanic Business

    "Alejandra brings deep legal and industry expertise to Cerulean and strengthens the management team as we advance our nanoparticle-drug conjugates in the clinic. Her experience will be highly relevant as we grow Cerulean," said , most recently as Associate General Counsel, where she served as a strategic advisor to the research and development, business development, manufacturing and commercial functions.

    Comment?